Promedior PRM-151 gets FDA orphan drug status
PRM-151 (rhPTX-2) is a recombinant form of human Pentraxin-2, an endogenous human protein that treats fibrosis by regulating the monocyte-derived cells. In a Phase 1 clinical study, PRM-151
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.